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The chemokine receptor CXCR2 binds several chemokines, some of them with functions yet to be defined.
In this issue of Immunity, Mei et al. (2010) generated CXCL5-deficient mice and described a prominent role
of CXCL5 in the regulation of CXCR2-dependent neutrophil trafficking during pulmonary host defense.Acute respiratory diseases, such as pneu-
monia, severe exacerbations of asthma,
acute lung injury (ALI), andacute respiratory
distress syndrome (ARDS), have a high
mortality rate and remain major challenges
in modern intensive care (Rubenfeld et al.,
2005).Theyarecharacterizedbyunderlying
inflammatory processes accompanied by
accumulation of neutrophils. Neutrophils
are pivotal for timely bacterial clearance,
but also cause lung injury and com-
plications when their recruitment is dysre-
gulated (Qiu et al., 2007). A tight balance
in regulation of immune cell recruitment is
critical for inflammation and antibacterial
immune defense.
Adhesion molecules, chemokines, and
their receptors regulate immune cell traf-
ficking. The chemokine receptor CXCR2
binds chemokines that are of key impor-
tance for neutrophil recruitment to the
lung (Reutershan et al., 2006). CXCR2-
activating chemokines include the ELR+
family of CXC chemokines CXCL1,
CXCL2, CXCL3, CXCL5, CXCL6 and, in
humans, CXCL7 and CXCL8 (IL-8).
Although CXCR2 function has been
studied fairly well, it is generally assumed
that the multiple CXCR2 ligands are
redundant. The specific physiological
function of some CXCR2-dependent
chemokines remains unclear.
Mouse CXCL5 is normally present in
naive mouse blood, where it is produced
and released by platelets. Importantly,
during bacterial challenge to the lung,
this chemokine is also upregulated in
lung epithelial cells. Consistent with this
expression pattern, anti-CXCL5 attenu-
ates neutrophil accumulation in rodent
models of lung inflammation (Jeyaseelan
et al., 2005). However, the story is more
complicated in CXCL5-deficient mice
(Mei et al., 2010).
The Duffy antigen receptor for chemo-
kines (DARC) has high affinity for inflam-matory CC and CXC chemokines, but
lacks the DRY motif in the second intra-
cellular loop and thus is unable to transmit
chemokine-mediated intracellular signals.
Previous studies suggested that DARC
might act as a ‘‘sink’’ and/or ‘‘storage
pool’’ for chemokines, which can bind to
DARC expressed on the erythrocyte and
endothelial cell surface (Fukuma et al.,
2003). In the blood of naive mice, most
of the chemokines capable of binding to
DARC do so. This allows the host to main-
tain directed chemokine gradients be-
tween blood (low) and infected or
damaged tissue (high) while preventing
elevated chemokine concentrations in
the circulation (Reutershan et al., 2009).
Disturbing the chemokine gradient by
changing the binding capability of DARC
can have both pro- or anti-inflammatory
effects (Reutershan et al., 2009; Zarbock
et al., 2007).
The importance of setting up and main-
taining chemokine gradients between
blood and tissues is supported by studies
in a group of humans who lack DARC
expression on their erythrocytes. Besides
resistance to malaria, DARC deficiency
was found to be related to increased inci-
dence and mortality from various malig-
nant diseases, most likely because
DARC-deficient people are unable to
maintain robust chemokine gradients
and effectively eliminate chemokines
from blood (Mayr et al., 2008).
The study by Mei et al. in this issue
uncovers an unexpected and important
role for CXCL5 in neutrophil trafficking in
lung inflammation (Mei et al., 2010). Para-
doxically, absence of CXCL5 improves
host defense in the lungs in response to
infection with E. coli. The authors propose
a mechanism implying that CXCL5 under
homeostatic and inflammatory conditions
not only acts as a bona fide neutrophil
chemoattractant but also binds DARCImmuand other nonsignaling receptors like
heparan sulfate proteoglycans. CXCL5
binding to DARC thus regulates the se-
questration and bioavailability of at least
two other crucial neutrophil chemoattrac-
tants, CXCL1 and CXCL2. This seems to
work because DARC has higher affinity
for CXCL5 than for CXCL1 or CXCL2
(Mei et al., 2010). When all these chemo-
kines are present, CXCL5 remains bound
to DARC, whereas CXCL1 and CXCL2 are
released and active. In the absence of
CXCL5, CXCL1 and CXCL2 are now
bound to DARC, and this dramatically
changes chemokine gradients, given
that their concentration in plasma (but
not in infected organs) is now decreased,
providing a steeper gradient leading to
increased accumulation of neutrophils
in the lungs, accelerated bacterial clear-
ance, and protection from severe
bacteria-induced pneumonia (Figure 1).
Although platelets serve as the main
source of CXCL5 under homeostatic
conditions, during severe E. coli infection
lung epithelial cells produce the bulk of
CXCL5. Under homeostatic conditions,
CXCL5 produced by platelets is loaded
on DARC expressed on the surface of
erythrocytes. With mild inflammation,
expression of CXCL5 by lung endothelial
cells is required for the recruitment and
accumulation of neutrophils. In this case,
CXCL5 has little effect on the concentra-
tion of CXCL1 and CXCL2 in plasma and
thus on the gradients. However, during
severe E. coli pneumonia, increased
expression of CXCL5 by lung endothelial
cells saturates the ability of DARC and
heparin sulfate proteoglycans to scav-
enge chemokines, which leads to dra-
matic increases of CXCL1 and CXCL2
concentrations in blood, destroys di-
rected gradients, and impairs neutrophil
recruitment. Increased circulating CXCL1
and CXCL2 can also help to recruit morenity 33, July 23, 2010 ª2010 Elsevier Inc. 7
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Figure 1. How CXCL5 Deficiency Influences Neutrophil Accumulation in the Lungs during Inflammation
Under homeostatic conditions, CXCL5 (purple dots), produced mainly by platelets, along with other chemokines such as CXCL1 (blue) and CXCL2 (orange) is
loaded onto DARC expressed on the surface of erythrocytes (RBC) (left). During E. coli- induced pneumonia, increased expression of CXCL5 by lung epithelial
cells provides a large amount of CXCL5, which saturates DARC, leading to release of CXCL1 and CXCL2 (middle). In the absence of CXCL5 (in knockout mice)
under inflammatory conditions, CXCL1 and CXCL2 bind to abundantly available DARC and heparan sulfate proteoglycans (HSPGs), which now are not blocked
by CXCL5. This leads to decreased concentrations of these chemokines in the blood, but not in the tissue, leading to a steeper chemokine gradient (arrows)
followed by increased neutrophil recruitment into the infected area and successful resolution of infection (right).
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ton et al., 2004), but in the setting of
E. coli pneumonia, the net effect seems
to be decreased neutrophil recruitment
to the infected lung when CXCL5 is
present. Earlier work had shown that
transport of CXCL1 and CXCL2 from the
lung to the blood promoted neutrophil
recruitment to the lungs in response to in-
tratracheal LPS (Quinton et al., 2004).
Perhaps the failure of gradients induced
by overwhelming CXCL5 expression
becomes only obvious in rampant pneu-
monia.
If most CXCL5 functions are mediated
through its ability to regulate the sequestra-
tion of other chemokines by DARC, inacti-
vation of DARC in Cxcl5/ mice should
revert the CXCL5-deficient phenotype.
Interestingly, DARC and CXCL5 double-
deficient mice showed only partially
decreased plasma levels of CXCL1, sug-
gesting that other chemokine-binding
moleculesare involved inCXCL5-regulated
chemokine scavenging. One of the poten-
tial candidatesproposed is heparan sulfate
proteoglycan (HSPG), which is widely
expressed by many cell types including
vascular endothelial cells. Indeed, the
authors found that CXCL5 is released
when heparin is allowed to compete for8 Immunity 33, July 23, 2010 ª2010 Elsevierheparan sulfate binding. Taken together,
the results show that CXCL5 regulates
CXCL1 and CXCL2 concentration in blood
by preventing their binding to DARC and
heparan sulfate proteoglycans.
Mei et al. provide insights into the differ-
ential functions of CXCL5, CXCL1, and
CXCL2 by uncovering a mechanism of
receptor competition between CXCL5
and other CXCR2-dependent chemo-
kines (Mei et al., 2010). The new CXCL5-
deficient mice will be an important tool
to shed light onto the role of this chemo-
kine in immune responses to various
infections and inflammatory conditions.
Has CXCL5 really only evolved to
regulate CXCL1 and CXCL2 concentra-
tions? This is hardly plausible. Perhaps,
the appropriate microbial stimulus for
CXCL5-dependent neutrophil recruitment
in response to infections remains to be
discovered. Perhaps CXCL5 is important
for neutrophil recruitment to organs other
than the lung. CXCL5 is expressed in
alveaolar type II epithelial cells, whereas
CXCL1 and CXCL2 are mainly expressed
by neutrophils and lung macrophages.
The present study does not address
whether the different cellular source may
have an impact on the specific functions
of these chemokines.Inc.Conserved chemokines like CXCL5
are under evolutionary pressure of the
ever-changing microbial environment to
protect their host. Future work will be
needed to identify infectious organisms
that are controlled by CXCL5-dependent
neutrophil recruitment. Studies using
other pulmonary and nonpulmonary
models of chronic inflammatory diseases
such as pulmonary hypertension, type
2 diabetes, atherosclerosis, and obesity
may elucidate the potential role of
CXCL5 in noninfectious inflammatory
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Little is known about the migration of plasma cell precursors to the lymph node medulla. In this issue of
Immunity, Fooksman et al. (2010) propose that this migration is largely independent of chemotactic cues
but follows a long linear walk of random orientation.Migration is a hallmark of immune cells. It
is key for their development, homeostasis,
and effector phase by bringing them at the
right time into contact with specific
factors, cells, and pathogens that are
localized at distinct sites in the complex
3D space that our body represents.
Although over the last 8 years two-photon
microscopy has been increasingly used to
investigate the dynamics of immune cell
behavior (Cahalan and Parker, 2008), so
far in vivo imaging of plasmablast (PB)
and plasma cell (PC) migration has not
been reported. In this issue of Immunity,
Fooksman et al. (2010) present a form of
movementwithin lymph nodes that seems
to be unique to PC precursors.
PCs are an important end product of
both T cell-dependent and T cell-indepen-
dent immune responses. They provide
humoral protection in acute infections
and can prevent future infections from
becoming established. In T cell-depen-
dent responses, antigen encounter in-
duces both T and B cells to move to the
boundary of the T cell-B cell zone where
they make cognate interactions with
each other. This leads to local B cell prolif-
eration (B blasts) before the B cells can
develop into PBs and PCs, by following
one of two distinct B cell differentiation
pathways: the extrafollicular pathway
providing an early wave of PCs (>day 3)and the follicular pathway providing a later
but usually more sustained wave of PCs
(>day 7), which typically produces anti-
bodies of increased affinity (MacLennan
et al., 2003, Tarlinton et al., 2008). PBs
that are cycling PC precursors are highly
migratory and home from the outer T cell
zone to the medullary cords of lymph no-
des (Cyster, 2003). In those niches, the
PB differentiate into noncycling PCs that
reside there for several days before dying
locally by apoptosis. In contrast, germinal
center (GC)-derived PCs typically leave
the organ as PBs to home to the bone
marrow or mucosal surfaces where they
can persist as PCs over years and main-
tain humoral memory.
The current study by Fooksman et al.
(2010) provides new insight into the way
PBsmigrate up to severalmillimeterswithin
lymph nodes going from the T cell-B cell
boundary or GC to the medulla. They
made use of a reporter mouse strain
expressing the YFP fluorochrome under
control of the Blimp-1 promoter tagging
activated B cells committed to PC differen-
tiation as YFP+, whereas naive and GC B
cells were YFP. At all time points after
immunization (days 4, 7, and 10), YFP+
PBs and/or PCs but not naive B cells were
enriched in the medulla. Although naive B
cells showed rapid migration (8 mm/min)
with many turns and confined to the B cellfollicle (Cahalan and Parker, 2008), early
YFP+ PBs on day 4 migrated more slowly
(3–5 mm/min), but with a persistent, long
linearmovement resulting inamuchgreater
displacement over time. At later time
points, YFP+ PCs found in the medulla
keptmoving at low speed (3mm/min) within
this confined compartment thereby
showing little displacement. Interestingly,
the speed and displacement of PB migra-
tion was only partially dependent on Gai
proteins that transmit signalsbychemokine
receptors. Consistent with this, the integrin
ligand ICAM-1 was sufficient for inducing
PB migration in linear trajectories in vitro.
The principal significance of this
elegant study is the observation of an
unusual strategy of lymphocyte migration
(Figure 1): in their search for the medulla,
PBs move in long linear tracks that
surprisingly show no directional bias
toward the target site. Once they get there
after several attempts, they are confined
to this compartment and differentiate
into PCs. This study questions the prevail-
ing view in the field that movements of
activated lymphocytes within lymphoid
organs are directed by chemokines (Ca-
halan and Parker, 2008).
This study raises several intriguing
questions. Why do medulla-homing PBs
adopt a strategy of random orientation?
At first glance it appears to be a rathernity 33, July 23, 2010 ª2010 Elsevier Inc. 9
